A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NYU Langone Laura & Isaac Perlmutter Cancer Center, New York

Memorial Sloan-Kettering Cancer Center, New York

New York-Presbyterian - Weill Cornell Medical Center, New York

Northwell Health Monter Cancer Center, Lake Success

New York Oncology Hematology - Albany Medical Center, Albany

Roswell Park Cancer Institute, Buffalo

Allegheny General Hospital, Pittsburgh

Maryland Oncology Hematology, P.A., Lanham

Virginia Cancer Specialists- Fairfax, Fairfax

Virginia Oncology Associates, Norfolk

University of North Carolina - Lineberger Comprehensive Cancer Center, Chapel Hill

Duke University Hospital, Durham

SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach

Moffitt Cancer Center, Tampa

SCRI - Florida Cancer Specialists- North Region, St. Petersburg

Vanderbilt University - Ingram Cancer Center, Nashville

Norton Cancer Institute - Broadway, Louisville

The Ohio State University College of Medicine, Columbus

Indiana University - Melvin & Bren Simon Cancer Center, Indianapolis

Barbara Ann Karmanos Cancer Institute, Detroit

The University of Chicago, Chicago

Washington University School of Medicine - Siteman Cancer Center, St Louis

GU Research Network/Urology Cancer Center, Omaha

Ochsner Cancer Institute, New Orleans

Texas Oncology - Tyler, Tyler

Texas Oncology- Memorial City, Houston

University of Texas - MD Anderson Cancer Center, Houston

University of Texas Health Science Center, San Antonio

Texas Oncology-Austin Central, Austin

Rocky Mountain Cancer Centers, Aurora

The University of Arizona Cancer Center, Tucson

Comprehensive Cancer Centers of Nevada - Southwest, Las Vegas

University of California Irvine, Irvine

Seattle Cancer Center Alliance, Seattle

Yale School of Medicine, New Haven

Dana Farber Cancer Institute, Boston